|
|
News Breaks | | | | January 11, 2013 | | 06:11 EDT |  | MR | Mindray Medical upgraded to Buy from Neutral at Goldman
Goldman upgraded Mindray citing relative underperformance, strong China and emerging markets growth, and overdone earnings concerns. Price target is $39.60. | |
|
News For MR From The Last 14 Days Check below for free stories on MR the last two weeks. |
|
|
| May 8, 2013 | | 09:34 EDT |  | MR | Mindray Medical downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill downgraded Mindray Medical due to weakness in emerging market sales following the Q1 report. | |
|
|
|
|
|
|
